Thanks for this. Had been looking forward to it. I personally use a “selective” early invasive strategy. And in my case I select based on TIMI risk score. I’m not aware of any comparison btw TIMi risk score vs Grace score.
The other aspect is “frailty” and the discordant results among some of the trials in this space, such as After 80, Mosca Frail, and the more recent Senior Rita. I wonder if you have any planned appraisals and guidance for those (or have you done it already and I missed it?).
You are a head of the game, Steve! Thank you pointing these out.
We are working on the reviews of MOSCA-FRAIL and SENIOR-RTIA and they will be posted next.
A "selective" early invasive approach is also what we recommend for patients with NSTEMI. Our discussion of TACTICS-TIMI 18, RITA 3 and ICTUS will be posted April 3, 2025.
Thanks for this. Had been looking forward to it. I personally use a “selective” early invasive strategy. And in my case I select based on TIMI risk score. I’m not aware of any comparison btw TIMi risk score vs Grace score.
The other aspect is “frailty” and the discordant results among some of the trials in this space, such as After 80, Mosca Frail, and the more recent Senior Rita. I wonder if you have any planned appraisals and guidance for those (or have you done it already and I missed it?).
You are a head of the game, Steve! Thank you pointing these out.
We are working on the reviews of MOSCA-FRAIL and SENIOR-RTIA and they will be posted next.
A "selective" early invasive approach is also what we recommend for patients with NSTEMI. Our discussion of TACTICS-TIMI 18, RITA 3 and ICTUS will be posted April 3, 2025.